Introduction
More than one billion of the world's poorest people are affected by neglected tropical diseases (NTDs), which are a group of parasitic, viral and bacterial infections that each year cause an estimated 534 000 deaths and a disease burden of 57 million disability-adjusted life-years (DALYs). 1 The World Health Organization (WHO) advocates five strategies for preventing and controlling NTDs: preventive chemotherapy, intensified case management, control of disease vectors, provision of clean water and sanitation and veterinary public health measures. 2 Historically, the development of drugs for these diseases has been limited by a lack of market incentives. 3 More recently, the formation of public-private partnerships for drug development has increased investment in research and development but the results have been uneven, with some diseases benefiting more than others. 4 For some NTDs, such as geohelminth infection, affordable and effective treatments do exist but their availability for people living in highly endemic areas is often limited. 4 For many others, treatment is inconvenient, poorly tolerated and expensive. A rational and comprehensive approach to disease control may, therefore, involve: (i) prevention strategies, including combined preventive chemotherapy (i.e. the treatment of more than one disease by the mass administration of more than one drug concurrently); (ii) improved access to clean water and sanitation; and (iii) the reduction of disease transmission by insect vectors. In addition, integrating efforts to control several NTDs into a single programme may reduce costs and streamline implementation. 1, [5] [6] [7] [8] Evidence from randomized controlled trials (RCTs) can provide valuable information about the relative merits of different preventive interventions. However, the evidence may be scattered across several different trials. Moreover, although several systematic reviews and meta-analyses have been carried out, typically each has considered only one or a few interventions for a single disease, thereby creating a fragmented picture of the evidence available from RCTs. To prioritize research into the control of NTDs and to make evidence-based decisions about prevention, we must know: (i) the extent to which the RCTs available and associated systematic reviews and meta-analyses address the most important questions about control and prevention; (ii) whether these studies leave modest or large gaps in evidence and (iii) whether any interventions have been found to be consistently effective.
To address these issues, we systematically collected evidence from RCTs available in the peer-reviewed literature on the prevention or control of the principal NTDs and from corresponding systematic reviews and meta-analyses. Our aims were to evaluate the evidence from RCTs, to identify interventions that were found to be effective in systematic reviews and meta-analyses, to determine whether different meta-analyses on the same topic yielded similar or conflicting conclusions and to identify gaps in the evidence available. disease), echinococcosis (hydatid cyst disease), foodborne trematode infection, geohelminth infection, human African trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, rabies, schistosomiasis and trachoma. We sought additional trials by reviewing our own literature collections, English-language systematic reviews, meta-analyses and Cochrane reviews, and the references of eligible publications we identified. The search strategy is given in detail in Table 1 (available at: http://www.who.int/bulwletin/volumes/92/5/13-129601).
For several diseases, prevention, control and treatment overlap. For example, preventive chemotherapy is a disease control strategy that encompasses treatment and prevention: in highly endemic areas, periodic mass drug administration both provides treatment for infected individuals and decreases the burden of disease in the community by reducing transmission and preventing new cases. 9 Currently, preventive chemotherapy is used for schistosomiasis, lymphatic filariasis, geohelminth infection, onchocerciasis and trachoma. 9 Our study included preventive chemotherapy trials, which were defined as trials in which chemotherapy was given to a group of participants regardless of their infection status (i.e. without testing or screening for disease), either by mass drug administration to the whole population or by targeting treatment at a known high-risk group (e.g. schoolchildren). We excluded trials of individual treatment in which only infected participants were randomized. We also excluded trials of diagnostic tests, pharmacokinetic studies in healthy volunteers, trials with nonhuman subjects, non-and pseudo-randomized trials and trials that addressed the prevention of disease complications (e.g. trials of footwear for preventing foot ulcers in leprosy patients). Furthermore, we excluded trials published only as abstracts, descriptions of planned studies, subgroup or secondary analyses of previously published RCTs and trials reported in languages other than Dutch, English, French, German, Portuguese or Spanish. When we found a preliminary report of clinical trial data that were later included in a more complete publication, we included only the final publication. Trials that addressed more than one disease were included in the data set only once, although, for completeness, they are listed in each relevant disease section in Table 2 .
Systematic reviews and metaanalyses
We carried out a separate search of PubMed and the Cochrane Database of Systematic Reviews to identify Englishlanguage meta-analyses and systematic reviews on the control or prevention of NTDs published on or before 31 December 2012. Eligible reviews had to contain at least one RCT that had been reported in a peer-reviewed publication and had to address the efficacy of any interventions used to prevent or control one of the 16 diseases of interest. We excluded articles on treatment, diagnosis, epidemiology, disease burden or the molecular biology, evolution or ecology of the etiological agent. We also excluded reviews that exclusively addressed animals (for example, vaccines in livestock) and protocols for planned reviews. For Cochrane reviews, we included only the most recent update. Systematic reviews had to include a methods section that described a comprehensive search strategy, with inclusion and exclusion criteria. A subset of systematic reviews included a meta-analysis that provided a formal quantitative synthesis of study results. We excluded three publications that were primarily reviews of reviews rather than of primary research data, though we read these publications to identify any additional suitable RCTs or systematic reviews. The search strategy is described in detail in Table 3 (available 
Data analysis
We extracted the following information from each published RCT: first author, publication year, journal title, study country or site, study design (i.e. cluster, crossover or neither), interventions, sample size and follow-up period. We used the "unit of randomization" for calculating sample sizes: for trials in which individual participants were randomized, the sample size was the total number of individuals randomized and, for cluster randomized trials, the sample size was the total number of clusters (for example, neighbourhoods or villages). For both individually and cluster randomized trials, the sample size was taken to be the total number of individuals or clusters initially randomized rather than the number remaining after accounting for those lost to follow-up. We noted whether the trial report included a funding statement and ascribed funding to one or more of four sources: (i) a government or other public agency, including WHO and national public organizations such as the National Institutes of Health in the United States of America; (ii) industry; (iii) a charity or foundation; and (iv) a university or hospital. For each of the 10 diseases for which data were available, we calculated the Pearson correlation coefficient for the correlation between the number of RCTs performed and the annual global burden of disease, expressed in DALYs, and between the total sample size and the annual global disease burden. 10 We obtained data on the disease burden of American trypanosomiasis, 11 dengue, 11 leishmaniasis, 11 For each systematic review, we extracted details of the first author, the publication year and the interventions addressed. Most meta-analyses and systematic reviews included both RCTs and nonrandomized studies. For each RCT, we extracted data on the sample size and the primary outcome. For reviews that included a meta-analysis, we recorded the effect size with 95% confidence intervals and, for all systematic reviews, we recorded the authors' conclusions, including their views on whether the intervention could be classified as: (i) likely to be effective; (ii) likely to be ineffective or (iii) of unknown efficacy due to a lack of sufficient evidence. When two or more reviews were available on the same intervention, we recorded whether they had similar or conflicting conclusions. Finally, we determined which RCTs in our RCT data set had not been included in a systematic review.
Results

Randomized controlled trials
The initial literature search for RCTs identified 2855 publications (Fig. 1 The total number of trials listed exceeds 258 because some addressed more than one disease concurrently: 8 addressed geohelminth infection and schistosomiasis, 2 addressed geohelminth infection and lymphatic filariasis, 1 addressed geohelminth infection and onchocerciasis and 1 addressed geohelminth infection, filariasis and schistosomiasis. b The sample size was the number of "units of randomization" in each trial, including the number of clusters in cluster randomized trials. It underestimates the number of individual participants. c A DALY is a year of life lost due to ill health, disability or early death associated with a disease. 10 d Trials were included in this category if any arm involved preventive chemotherapy. e Includes environmental modification, biological control, insecticide spraying and insecticide-treated bednets, curtains and clothing. f This trial compared four different lengths of intradermal needle for intradermal injection and an epidermal abrasion system with intramuscular delivery of rabies vaccine. g The sum of the number of trials in each intervention category does not add to 27 because several trials contained more than one modality (e.g. sanitation and preventive chemotherapy).
from the bibliographies of systematic reviews or meta-analyses. The final analysis included 246 publications containing details of 258 RCTs (Appendix A, available at: https://stanford.box.com/s/ nm7ri7xnxq58m744gcl5). Table 2 shows, for 11 NTDs, the number of RCTs on prevention or control performed, the total sample size and the annual global disease burden. Geohelminth infection was studied most (51 RCTs with a total sample size of 22 848), followed by leishmaniasis (46 RCTs with a total sample size of 22 758) and rabies (34 RCTs with a total sample size of 5176). No RCT had been performed on the prevention or control of five diseases: cysticercosis, dracunculiasis, echinococcosis, foodborne trematode infection and human African trypanosomiasis. There was no significant correlation between disease burden and either the number of RCTs (ρ = 0.12, P = 0.73) or the total sample size (ρ = −0.38; P = 0.28). Although the disease burden was greatest for lymphatic filariasis, only 10 RCTs had been performed. Table 4 shows that most RCTs were conducted in the WHO Region of the Americas, the South-East Asia Region or the African Region. Only 10 RCTs (3.9%) were multicentre trials. There were 71 (27.5%) cluster randomized trials. Most trials were publicly funded (55.8%) or had no reported funding source (25.6%) and only 10.1% were funded by industry. The median sample size was 151 (interquartile range: 36 to 553).
Overall, 113 of the 258 RCTs (43.8%) involved vaccines, 99 (38.4%) involved topical or oral chemoprophylaxis and 39 (15.1%) involved interventions that targeted insect vectors, such as insecticide-treated bednets or indoor residual spraying. In addition, 80 (31.0%) had one or more preventive chemotherapy arms -either mass drug administration or targeted treatment. Few trials addressed the delivery of preventive chemotherapy: only 10 considered dosing intervals, 4 considered the choice of target population, 2 considered the population coverage needed for mass drug administration and 1 considered how best to deliver preventive chemotherapy. The other preventive chemotherapy trials either compared a drug with placebo or compared two or more drugs. Only 12 trials addressed co-treatment of more than one disease by mass drug administration. Preventive chemotherapy is the main intervention for four diseases -lymphatic filariasis, onchocerciasis, schistosomiasis and geohelminth infections -and is a key component in the control of trachoma. 9, 13 Although 80 of 112 RCTs on these five diseases had a targeted treatment or mass drug administration arm, again very few addressed how best to deliver preventive chemotherapy: only 10 investigated different time intervals for drug distribution, 2 considered population coverage, 4 considered the target population and 1 considered the method of drug distribution. Moreover, of the 80 RCTs, 27 compared mass treatment and placebo, whereas 24 compared different drugs.
Systematic reviews and metaanalyses
The literature search identified 31 publications that reported one or more systematic reviews, with or without a formal meta-analysis (Fig. 2, The sum of the number of trials in each location exceeds 258 because some were multicentre trials. c The mean and the median were calculated using the "unit of randomization" in each trial, including the number of clusters in cluster randomized trials. Consequently, the number of individual participants was underestimated. When the number of participants in cluster randomized trials was taken into account, when available, rather than the number of clusters, the median sample size was 396 (interquartile range: 123-1425). 40 3 on schistosomiasis, [41] [42] [43] 1 on geohelminths 43 and 1 on American trypanosomiasis. 44 Details of the systematic reviews are given in Appendix B (available at: https://stanford.box. com/s/af4co496bynqxlfwnlgc).
Ap p e n d i x C ( a v a i l a b l e a t : https://stanford.box.com/s/ftoxgslppc4d9qzno3j5) lists the RCTs included in each review. Overall, only 79 of the 258 RCTs (30.6%) were included in a systematic review: 31 (12.0%) were included only in a systematic review without a meta-analysis, 40 (15.5%) were included only in a systematic review with a meta-analysis and 8 (3.1%) were included in both a systematic review without a meta-analysis and one with a meta-analysis.
Nineteen interventions had been assessed by a single systematic review (Table 5) . Of the 19, 14 were found to be effective, 3 were found to be ineffective and, for 2, there was insufficient evidence to judge efficacy. Another 17 interventions had been assessed by two or more systematic reviews (Table 6) . Of the 17, 8 were consistently found to be effective (all had been assessed in a meta-analysis), 1 was consistently found to be ineffective and, for 8, different reviews produced conflicting conclusions. For 4 of the 8 interventions on which conclusions conflicted, different systematic reviews concluded either that the intervention was likely to be effective or that there was insufficient evidence; for 1 other intervention, different systematic reviews concluded either that the intervention was likely to be ineffective or that there was insufficient evidence; and for the remaining 3 interventions, different reviews reported all possible conclusions (i.e. likely to be effective, likely to be ineffective and insufficient evidence). Only interventions for trachoma, leprosy and schistosomiasis were consistently judged to be effective by more than one systematic review. However, interventions for American trypanosomiasis, geohelminth infection, onchocerciasis and lymphatic filariasis were judged effective by the one systematic review in which each had been assessed.
For Buruli ulcer and rabies, no systematic review of a prevention or control intervention containing a peerreviewed RCT had been performed, though RCTs had been carried out. For cysticercosis, dracunculiasis, echinococcosis, foodborne trematode infection and human African trypanosomiasis, neither a systematic review nor an RCT had been performed.
Discussion
Our analysis of 258 RCTs and 32 systematic reviews provides a summary of the evidence available on the prevention and control of NTDs and identifies gaps in that evidence. Although prevention is likely to be more cost-effective than treatment for these diseases, 45, 46 far fewer trials of prevention than treatment have been carried out. 47 We found that RCTs 
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Prevention and control of neglected tropical diseases Shanthi Kappagoda & John PA Ioannidis on prevention or control had been performed for only 11 of the 16 principal NTDs and that systematic reviews had been performed for only 9. Most RCTs had not been included in a systematic review. We identified 8 interventions that were consistently found to be effective in two or more systematic reviews: topical tetracycline and oral azithromycin chemotherapy for the prevention of trachoma; BCG vaccination, dapsone and acedapsone chemoprophylaxis for Likely to effective: Al-Muhandis 2011, 15 Erlanger 2008 14 NA, not applicable; RCT, randomized controlled trial. a This review included two RCTs and concluded: "[There is]… evidence that face washing can be effective in increasing facial cleanliness and in reducing severe trachoma, but its effect in reducing active trachoma is inconclusive. In another trial, there was no evidence of effect of face washing alone or in combination with tetracycline in reducing active trachoma in children with already established disease. " b This paper concluded that there was "weak supportive evidence" for the effectiveness of facial cleanliness and environmental modification but the evidence was minimal.
Prevention and control of neglected tropical diseases Shanthi Kappagoda & John PA Ioannidis the prevention of leprosy; and artesunate, artemether and praziquantel chemoprophylaxis for schistosomiasis ( Table 6 ). For another 14 interventions, a single review concluded that they were effective (Table 5) . However, for 8 interventions for which two or more reviews were available, conclusions were conflicting (Table 6) . A range of nonpharmacological interventions for disease control was reported. Future meta-analyses would be made easier by standardizing the design of trials on vector control strategies, including habitat modification, the use of insecticide-impregnated materials and spraying for dengue and leishmaniasis. Furthermore, most vector control trials for leishmaniasis and dengue did not consider human disease as an outcome and there is a need for more research on the relationship between vector control and human disease to justify such interventions. In particular, research on leishmaniasis and dengue is very different from that on trachoma: the recent literature on trachoma reports that collaborative, large-scale studies have been carried out, study designs and protocols have been published and efforts have been made to standardize definitions and outcome measures. 13, 48, 49 There was either limited evidence that trachoma could be prevented by environmental improvements, such as increased access to sanitation, or conflicting conclusions in meta-analyses and systematic reviews. However, since such interventions may have broader benefits for other conditions, such as childhood diarrhoea 50, 51 and geohelminth infection, 52 and may reduce overall childhood mortality, 53 it may not be a good use of resources to carry out further studies into their effect on this one disease.
Publications on the five NTDs for which no systematic review or RCT had been performed -cysticercosis, dracunculiasis, echinococcosis, foodborne trematode infections and human African trypanosomiasis -generally focused on treatment. 47 These diseases all have a focal form of transmission, which means that controlled trials would require the collaboration of veterinary public health experts, clinical researchers and behavioural health experts. For two diseases -rabies and Buruli ulcer -RCTs had been carried out but no systematic review containing an RCT was found in the literature search. For example, the systematic reviews found on rabies prevention did not include RCTs from peer-reviewed publications.
54,55
Limitations
Our study has several limitations. First, we did not consider unpublished findings or the results of trials that were published only as abstracts because such material is difficult to identify systematically and formal peer-reviews have not been carried out. Consequently, we do not know the extent to which publication or selective reporting bias may have influenced the reliability of the evidence available. However, it is unlikely that such biases would completely invalidate the large preventive effects observed. Second, we did not conduct our own systematic review or meta-analysis because this would have been difficult to achieve for the dozens of different interventions used for 16 diseases. However, the reviews and metaanalyses we identified provide a summary of the evidence available and our analysis highlights those interventions that remain controversial and indicates those that need to be evaluated in systematic reviews and meta-analyses and those that need to be tested in RCTs. Third, we avoided adopting a specific conclusion when different systematic reviews and metaanalyses reached different conclusions. Instead, we registered the discrepancy, which may have reflected differences in eligibility criteria, data analysis or interpretation. [56] [57] [58] For example, different eligibility criteria were used in the reviews of chemical vector control for dengue, 14, 34, 35 different eligibility criteria and different methods for calculating summary effect measures were used in the meta-analyses of albendazole for lymphatic filariasis, 27, 28 and mainly the same evidence was interpreted in different ways in the reviews of eye or face washing and environmental improvements for trachoma. 30, 32, 33 Although trials of individual treatments can help in selecting drugs for use in mass drug administration programmes, such trials are not usually designed to address rare but serious side-effects or drug resistance, both of which are concerns in large-scale programmes. In addition, these trials rarely include nursing or pregnant women, who could also benefit from preventive chemotherapy. [59] [60] [61] Furthermore, while the evidence supporting the use of individual drugs included in mass drug administration programmes may be adequate, there are few reports of prevention or treatment trials involving combinations of drugs for several diseases, which are essential for evaluating integrated preventive chemotherapy. 47 In conclusion, our study provides an overview of what is and is not known about the effectiveness of prevention and control measures for the principal NTDs. Where strong evidence is available, it can be used to guide the introduction and scale-up of prevention and control programmes; where gaps in evidence have been identified, the result should be new RCTs on prevention and control measures, although carrying out such trials in endemic areas is challenging. Moreover, these trials may have to be large to detect significant effects in the population and the costs may be prohibitive. However, a considerable amount of money has already been invested in, for example, mass drug administration programmes. Such programmes could only become more acceptable and financially viable if the most effective and costeffective ways of delivering preventive chemotherapy were identified. ■ Funding: Shanthi Kappagoda was supported in part by grant HS000028 from the Agency for Healthcare Research and Quality. The funding body did not influence the design or implementation of the study or the decision to publish and the authors alone are responsible for the content of this paper.
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Shanthi Kappagoda & John PA Ioannidis 摘要 被忽视的热带病的预防和控制 ：随机试验、系统评价和元分析概述 目的 分析来自有关预防和控制被忽视热带疾病 （NTD） 随机对照试验（RCT）的证据并识别缺少证据的领域。 方 法 在 科 克 伦 对 照 试 验 注 册 中 心 和 PubMed 检 索 RCT，在科克伦系统评价数据库和
Resumen
La prevención y el control de enfermedades tropicales desatendidas: una visión general de ensayos aleatorios, exámenes sistemáticos y metaanálisis
Objetivo Analizar las evidencias procedentes de ensayos controlados aleatorios (RCT, por sus siglas en inglés) sobre la prevención y el control de enfermedades tropicales desatendidas e identificar las áreas en las que se carece de evidencias. Métodos Se buscaron RCT en el Registro Central Cochrane de Ensayos Controlados y en PubMed, así como metaanálisis y exámenes sistemáticos en la Base de Datos Cochrane de Revisiones Sistemáticas y en PubMed, en ambos casos, desde sus comienzos hasta el 31 de diciembre de 2012. Resultados En total, se hallaron 258 RCT acerca de la infección por el parásito Trypanosoma cruzi, la úlcera de Buruli, el dengue, las infecciones por geohelmintiasis, la leishmaniasis, la lepra, la filariasis linfática, la oncocercosis, las rabias, la esquistosomiasis o el tracoma. No se encontraron RCT sobre la cisticercosis, la equinococosis, las nematodiasis transmitidas por los alimentos, la dracunculosis ni la tripanosomiasis africana humana. Las enfermedades más estudiadas fueron la infección por geohelmiantiasis (51 RCT) y la leishmaniasis (46 RCT). Las vacunas, quimioprofilaxis e intervenciones cuyo objetivo eran los insectos que actúan como vectores quedaron evaluadas en 113, 99 y 39 RCT, respectivamente. Unos pocos ensayos abordaron la mejor manera de administrar quimioterapia preventiva, como la elección del intervalo de dosificación (10) o la población objetivo (4), la cobertura de la población requerida para reducir la transmisión (2) o el método de distribución de medicamentos (1). Se encontraron 31 publicaciones que incluían 32 exámenes sistemáticos (16 con metaanálisis y 16 sin metaanálisis) sobre la infección por el parásito Trypanosoma cruzi, el dengue, los geohelmintos, la leishmaniasis, la lepra, la filariasis linfática, la oncocercosis, la esquistosomiasis y el tracoma. En su conjunto, solo incluyeron 79 de los 258 RCT publicados (30,6 %). De las 36 intervenciones evaluadas, 8 se consideraron eficaces en más de un examen. Conclusión Se hallaron pocos RCT sobre la prevención y el control de las principales enfermedades tropicales desatendidas. Los ensayos sobre la mejor manera de administrar quimioterapia preventiva fueron especialmente escasos.
